Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer

(2019) J F Liu et al.   ANNALS OF ONCOLOGY

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

(2018) Noel Clarke et al.   LANCET ONCOLOGY

The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials

(2018) Xiao Xia Guo et al.   Cancer Management and Research

18F-Fluoromisonidazole Kinetic Modeling for Characterization of Tumor Perfusion and Hypoxia in Response to Antiangiogenic Therapy

(2017) Milan Grkovski et al.   JOURNAL OF NUCLEAR MEDICINE

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

(2017) Eric Pujade-Lauraine et al.   LANCET ONCOLOGY

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

(2017) Likun Li et al.   Science Signaling

2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity

(2017) Parker L. Sulkowski et al.   Science Translational Medicine

The mTOR and PP2A Pathways Regulate PHD2 Phosphorylation to Fine-Tune HIF1α Levels and Colorectal Cancer Cell Survival under Hypoxia

(2017) Giusy Di Conza et al.   Cell Reports

Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

(2017) Likun Li et al.   Science Signaling

Combenefit: an interactive platform for the analysis and visualization of drug combinations

(2016) Giovanni Y. Di Veroli et al.   BIOINFORMATICS

Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay

(2016) Yulia V. Surovtseva et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture

(2015) Yanyan Jiang et al.   LUNG CANCER

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

(2014) Joyce F Liu et al.   LANCET ONCOLOGY

Hypoxic Stress Facilitates Acute Activation and Chronic Downregulation of Fanconi Anemia Proteins

(2014) Susan E. Scanlon et al.   MOLECULAR CANCER RESEARCH

Development of an assay to measure mutagenic non-homologous end-joining repair activity in mammalian cells

(2013) Ranjit S. Bindra et al.   NUCLEIC ACIDS RESEARCH

Hypoxia-Induced Epigenetic Regulation and Silencing of the BRCA1 Promoter

(2011) Y. Lu et al.   MOLECULAR AND CELLULAR BIOLOGY

Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition

(2011) P. M. Krawczyk et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment

(2010) N. Chan et al.   CANCER RESEARCH

Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130

(2010) D. C. Hegan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2-Mutated Ovarian Carcinoma

(2009) W. Sakai et al.   CANCER RESEARCH

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance

(2008) N. Chan et al.   CANCER RESEARCH